Secrecy and transparency of medicines licensing in the EU

Lancet

Volumn 352, Issue 9126, 1998, Pages 480-482

  Abraham, John ^a   Lewis, Graham ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENTIALITY; DRUG LEGISLATION; DRUG MARKETING; EUROPEAN UNION; LICENSING; MEDICAL INFORMATION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032497152     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11282-X     Document Type: Note

References (7)

1. 1 European Medicines Evaluation Agency. Interim report on the consultation exercise on transparency and access to documents at the EMEA, April 28, 1997.
2. 2 Anon. Access to Commission documents. Regulatory Affairs Journal 1994; 5: 481.
3. 3 National Consumer Council. Secrecy and Medicines in Europe, 1994: 14.
4. 4 Health Action International. Secrecy Campaign Information Pack. 1992: 2.
5. 5 Brown P. EC unease over UK MCA approach. Scrip 1990; 1564: 9.
6. 6 Anon. British oppose more CPMP transparency. Scrip 1991; 1602: 5.
7. 7 Warden J. Drug policy. BMJ 1993; 306: 1228.